Biomarin Pharmaceutical (BMRN) Interest & Investment Income (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted Interest & Investment Income of $22.6 million for Q1 2026, up 17.44% on a QoQ basis from $19.2 million in Q4 2025, and up 18.66% year-over-year from $19.0 million in Q1 2025.
Biomarin Pharmaceutical (BMRN) Interest & Investment Income (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Interest & Investment Income history runs 18 years deep, the most recent figure standing at $22.6 million for Q1 2026.
- Quarterly Interest & Investment Income rose 18.66% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.5 million (up 5.26% YoY) and the FY2025 annual result came in at $74.9 million, changed 0.03% from the prior year.
- Interest & Investment Income was $22.6 million for Q1 2026 at Biomarin Pharmaceutical, up from $19.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $22.6 million in Q1 2026 and bottomed at $1.8 million in Q1 2022.
- A 5-year average of $14.6 million and a median of $17.9 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 43.97% — and 2023, when it soared 556.21%.
- Biomarin Pharmaceutical's Interest & Investment Income stood at $8.7 million in 2022, then surged by 107.16% to $18.0 million in 2023, then dropped by 2.02% to $17.7 million in 2024, then climbed by 8.65% to $19.2 million in 2025, then grew by 17.44% to $22.6 million in 2026.
- Business Quant data shows BMRN's Interest & Investment Income at $22.6 million in Q1 2026, $19.2 million in Q4 2025, and $17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Biomarin Pharmaceutical | 11.41 Bn | 9.18 Bn | 571.21 Mn | 22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.56 Mn |
| Dec 31, 2025 | 19.21 Mn |
| Sep 30, 2025 | 17.85 Mn |
| Jun 30, 2025 | 18.83 Mn |
| Mar 31, 2025 | 19.01 Mn |
| Dec 31, 2024 | 17.68 Mn |
| Sep 30, 2024 | 18.05 Mn |
| Jun 30, 2024 | 19.79 Mn |
| Mar 31, 2024 | 19.37 Mn |
| Dec 31, 2023 | 18.04 Mn |
| Sep 30, 2023 | 15.74 Mn |
| Jun 30, 2023 | 12.61 Mn |
| Mar 31, 2023 | 11.94 Mn |
| Dec 31, 2022 | 8.71 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 1.82 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 4.47 Mn |